Form 4: Supernus Pharmaceuticals SVP, Chief Medical Officer, Jonathan Rubin, Reports Changes in Beneficial Ownership

Jonathan Rubin, SVP, Chief Medical Officer of Supernus Pharmaceuticals, reports changes in beneficial ownership, including the acquisition of common stock through the Employee Stock Purchase Plan and the vesting of Performance Share Units.

Summary

• Jonathan Rubin, the SVP, Chief Medical Officer of Supernus Pharmaceuticals, filed a Form 4 to report changes in beneficial ownership.
• The report indicates that Rubin acquired 310 shares of common stock through the company's Employee Stock Purchase Plan.
• Rubin was also awarded 1,875 Performance Share Units on February 22, 2024, a portion of which vested upon achievement of individual performance objectives established on June 24, 2024.
• Following these transactions, Rubin directly owns 6,905 shares of Supernus Pharmaceuticals common stock and 1,875 Performance Share Units.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine filing indicating insider transactions, with no clear positive or negative implications for the company's overall performance.

Positives

• The acquisition of shares through the Employee Stock Purchase Plan demonstrates Rubin's investment in the company's future.
• The vesting of Performance Share Units aligns Rubin's compensation with the achievement of individual performance objectives, incentivizing him to contribute to the company's success.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. They are closely watched by investors to gauge management's sentiment and confidence in the company's prospects.

Stakeholder Impact

• The reported transactions provide shareholders with insight into the actions of a key executive.
• The vesting of Performance Share Units aligns the executive's interests with those of the shareholders.

Key Dates